Citadel Advisors
CSBR icon

Citadel Advisors’s Champions Oncology CSBR Stock Holding History

Citadel Advisors’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,800
Closed -$116K – 12936
2025
Q2 		$116K Buy
15,800
+1,200
+8% +$8.47K ﹤0.01% 11200
2025
Q1 		$127K Buy
14,600
+8,100
+125% +$82.1K ﹤0.01% 11132
2024
Q4 		$55.7K Buy
+6,500
New +$32.7K ﹤0.01% 12277
2024
Q3 		– Sell
-3,300
Closed -$17.1K – 14353
2024
Q2 		$17.1K Buy
3,300
+700
+27% +$3.41K ﹤0.01% 12768
2024
Q1 		$12.7K Buy
2,600
+1,900
+271% +$11.1K ﹤0.01% 13345
2023
Q4 		$3.79K Sell
700
-500
-42% -$2.79K ﹤0.01% 13558
2023
Q3 		$7.46K Sell
1,200
-6,000
-83% -$37.9K ﹤0.01% 13256
2023
Q2 		$45.3K Buy
7,200
+1,100
+18% +$5.68K ﹤0.01% 11919
2023
Q1 		$24.5K Buy
6,100
+1,600
+36% +$6.84K ﹤0.01% 12908
2022
Q4 		$20.3K Sell
4,500
-179,600
-98% -$1.17M ﹤0.01% 13135
2022
Q3 		$1.38M Sell
184,100
-35,200
-16% -$294K ﹤0.01% 6318
2022
Q2 		$1.77M Buy
219,300
+31,100
+17% +$238K ﹤0.01% 5795
2022
Q1 		$1.53M Buy
+188,200
New +$1.51M ﹤0.01% 6683

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors's CSBR Position: Q4 2025 in Review

Citadel Advisors sold out of Champions Oncology (CSBR) in Q4 2025, closing a stake of 16,326 shares — an estimated $106K sold.

Citadel Advisors first reported a position in CSBR in Q3 2016 and held it in 14 quarters. The position peaked at $280K in Q3 2022. 27 funds tracked by Wall St. Rank hold CSBR as of Q4 2025.

  • Citadel Advisors reported no remaining Champions Oncology position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 16,326 Champions Oncology shares in Q4 2025, an estimated $106K.
  • Citadel Advisors first reported a position in Champions Oncology in Q3 2016 and held it in 14 quarters.
  • Citadel Advisors's Champions Oncology position peaked at $280K in Q3 2022.
  • 27 funds tracked by Wall St. Rank held Champions Oncology as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.